BDX teams up with the Penn Institute for Immunology and Immune Health to launch a high-parameter immune profiling study.

STEMart, a US-based provider of comprehensive services for all phases of medical device development, has announced the availability of its robust In Vitro Micronucleus Test service to meet the ...

IGIB, has launched India's first Centre of Excellence for Single-Cell Multiomics to enhance research in immunity, cancer, and ...

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...

Ace Therapeutics recently launched in vivo efficacy testing services for IBD drug candidates. Ace Therapeutics, a preclinical ...

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic ...

A research team at Oregon Health & Science University (OHSU) has discovered a promising new drug combination that may help people with acute myeloid leukaemia overcome resistance to one of the most ...

Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to ...

Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.

Human immunodeficiency virus (HIV) infections are still fairly common and an estimated 40 million people worldwide are ...